[Skip to Content]
[Skip to Content Landing]
Views 3,212
Citations 0
News From the Food and Drug Administration
August 20, 2019

Another Option for Hypoactive Sexual Desire

JAMA. 2019;322(7):604. doi:10.1001/jama.2019.11515

The FDA recently approved bremelanotide for acquired generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It’s the first “as-needed” treatment for HSDD, a common condition characterized by low libido that causes distress or interpersonal difficulty and isn’t attributed to a coexisting medical or psychiatric condition, relationship problems, or medications.